
Updated ASH / ISTH Clinical Guidelines 2024
American Society of Hematology/International Society on Thrombosis and Haemostasis 2024 updated guidelines for treatment of venous thromboembolism in pediatric patients.
Clinical Takeaways:
Final authority remains 2023 ASH guidelines until full 2024 publication—but updates add precision, especially in non-surgical VTE and cancer-associated scenarios.The 2024 iteration refines duration decision-making using newer DOACs and better incorporates bleeding risk and patient preferences.
Stay tuned for full 2024 guidelines expected in Blood Advances or via ASH/ISTH websites.
Title: American Society of Hematology/International Society on Thrombosis and Haemostasis 2024 updated guidelines for treatment of venous thromboembolism in pediatric patients
Authors: Paul Monagle, Muayad Azzam, Rachel Bercovitz, Marisol Betensky , Rukhmi Bhat, Tina Biss, Brian Branchford, Leonardo R. Brandão, Anthony K. C. Chan, E. Vincent S. Faustino, Julie Jaffray, Sophie Jones, Hassan Kawtharany, Bryce A. Kerlin, Nicole Kucine, Riten Kumar , Christoph Male , Marie-Claude Pelland-Marcotte, Leslie Raffini, Chittalsinh Raulji, Reem A. Mustafa.
See detailed information in Hemostasis Today.
-
Aug 4, 2025, 06:00Genotype–Phenotype Understanding in Hemophilia B: Commentary on Factor IX Missense Variants
-
Aug 4, 2025, 05:47National Health Center Week – Recognizing the Vital Role of HTCs in Specialized Care
-
Aug 4, 2025, 05:33Women with Hemophilia Finally Heard: “DISMISSED” Premieres August 22
-
Aug 4, 2025, 04:58Women with Inherited Bleeding Disorders: Overcoming Diagnostic and Clinical Challenge
-
Aug 4, 2025, 01:37EAHAD Launches Italian Booklet to Support Young Girls With Bleeding Disorders During Their First Period
-
Aug 4, 2025, 01:59Michael Makris Posts Haemophilia Journal Article Reassessing UK Blood Inquiry
-
Aug 4, 2025, 01:09Manuel Monreal Congratulates Authors Ahead of JTH Publication: VTE-Predict Score Validated in RIETE Cohort
-
Aug 3, 2025, 17:48Nathan Connell: What Is The "Mild Equivalent" For Hemophilia A That Is Achieved While on Emicizumab?
-
Aug 3, 2025, 03:54Cedric Hermans on the Inspiring Impact of the WFH Humanitarian Aid Program Worldwide
-
Aug 2, 2025, 20:14Sebastian Szmit Shares Patients’ Perspectives on Decision‑Making for Antithrombotic Therapy in Advanced Cancer
-
Jul 28, 2025, 14:55HORIBA Decoding High Efficiency in Hematology Lab: Free Online Workshop
-
Jul 26, 2025, 17:56HIPEITHO Trial Achieves Remarkable Enrollment Milestone Across 72 Sites in the US and Europe
-
Jul 16, 2025, 15:04Toward Hemophilia Gene Therapy for All? Insights from Prof. Flora Peyvandi in Blood Advances
-
Jul 14, 2025, 16:39Dr. Philipp Bücke: MRI Proven as No.1 Choice for Accurate TIA Diagnosis
-
Jul 13, 2025, 16:05EMA and HMA Mark a Key Step with 1st AI Observatory Report
-
Aug 4, 2025, 05:20NBCA: Alexis’s DVT Diagnosis Came Without Warning - Learn How She Caught It Early
-
Aug 4, 2025, 00:50NBCA: After Losing Her Daughter to a Blood Clot, Charita Fights to Save Others
-
Aug 3, 2025, 18:10Andrew Agwunobi Congrats Dr. Oladipo Cole and The Whole Team at the Connecticut Bleeding Disorder Center
-
Aug 3, 2025, 12:03Elias Bouchi Presents Werfen EEMEA Talks on Hemostasis: Clot Stories Season 3
-
Jul 31, 2025, 15:37Sano Genetics: “Unreasonable” Leadership with Benny Sorenson of Hemab